Switching from conventional therapy to Crysvita (burosumab) leads to clinically relevant reductions in pain and fatigue, and better quality of life, in children with X-linked hypophosphatemia (XLH) ages 5 to 12, according to data from a Phase 3 clinical trial. These findings in patient-reported outcomes add to previous results from this trial showing that the therapy significantly lessened the severity of bone-related symptoms and aided growth in pediatric patients, ages 1 to 12. Altogether, these data…

You must be logged in to read/download the full post.